Clinical comparison · Menopause & vasomotor symptoms · Updated 2026-07-02
Transdermal and oral estradiol deliver the same molecule by different routes. This table reproduces, verbatim, the labeled dosing and the published route-specific findings that clinicians weigh — it does not rank one route above the other. Route selection is an individual clinical decision made with your prescriber.
Every value below is reproduced verbatim from an FDA prescribing-information document or a published clinical trial, and each cell links to its source. This page does not rank the two options, does not declare one safer or more effective, and is not medical advice.
| Dimension | Transdermal estradiol | Oral estradiol |
|---|---|---|
| Route of administration | Transdermal patch or gel applied to skin[1] | Oral tablet taken by mouth[2] |
| Hepatic first-pass metabolism | Bypassed — absorbed through skin into systemic circulation[2] | Undergoes hepatic first-pass metabolism[2] |
| Venous thromboembolism (VTE) signal | No significant increase in VTE risk vs non-use in the cohort[3] | Associated with an increased VTE risk vs non-use in the cohort[3] |
| Typical systemic dose (VMS) | Patch 0.025-0.1 mg/day; gel 0.25-1 mg/day[1] | 0.5-2 mg once daily[2] |
| Endometrial protection when uterus present | Requires added progestogen to protect the endometrium[2] | Requires added progestogen to protect the endometrium[2] |
| Pregnancy category | Contraindicated in pregnancy (FDA category X)[1] | Contraindicated in pregnancy (FDA category X)[1] |
What BMJ 2019 measured
A large nested case-control study of hormone therapy and VTE. It reported that oral estrogen was associated with a higher VTE risk versus non-use, while transdermal estrogen was not associated with an increased risk. The finding is a population-level association, not an individual guarantee. Transdermal vs oral VTE (BMJ 2019)
How the route facts are framed
First-pass metabolism and dosing come directly from the FDA Climara label and the NAMS 2022 position statement. Both routes deliver 17-beta-estradiol; the differences shown are route effects, not different drugs. NAMS 2022 Hormone Therapy Position Statement
Yes. Both deliver 17-beta-estradiol. The difference is the route: transdermal is absorbed through skin and bypasses hepatic first-pass metabolism, while oral estradiol is metabolized by the liver first (NAMS 2022).
It reported that oral estrogen was associated with an increased venous thromboembolism risk versus non-use, whereas transdermal estrogen was not associated with an increased risk in the same cohort. This is a population association, not individual medical advice.
If you have a uterus, added progestogen is required with either route to protect the endometrium, per the NAMS 2022 position statement.
Editorial reviews from ClearHormones of telehealth providers in this category. These are not treatment recommendations, and prescribing decisions rest with a licensed clinician.